抗纤维化治疗对IPF中MMP降解CRP新表位水平预后预测的差异效应
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is characterized by an increase in proteolytic enzymes, including matrix metalloproteinases that degrade the extracellular matrix and markers of localized inflammation.…
要点
- 所有检测新表位的正斜率均与PTFS显著降低相关。
- 体外实验中尼达尼布而非吡非尼酮可减少内皮细胞CRPM形成。
核心结论
- IPF患者中CRPM血清水平正/升高斜率与尼达尼布治疗者更差的5年生存相关,而与吡非尼酮治疗者无关。
- 尼达尼布而非吡非尼酮在体外减少内皮细胞CRPM形成,提示尼达尼布/CRPM相关效应部分由内皮细胞介导。
研究设计与样本
- 在基线及尼达尼布或吡非尼酮治疗6个月内测量血清CRPM、III型胶原、6型胶原片段及前胶原6浓度。
- 分析新表位及其纵向动力学(正/升高或负/下降斜率)与死亡率、无进展及无移植生存(PTFS)的关联,并通过细胞培养实验探究抗纤维化治疗对新表位动力学的作用机制。
主要发现
- 患者平均年龄71岁,女性占20.7%。
- 基线测量后,50%接受尼达尼布、35%接受吡非尼酮、15%未接受抗纤维化治疗。
- 所有检测新表位的正斜率均与PTFS显著降低相关。
- 倾向评分匹配证实CRPM正斜率与PTFS受损的关联,且两个队列中PTFS效应均由尼达尼布治疗亚组驱动,队列间验证可见。
关键数值与推荐
- 所有检测新表位正斜率均与PTFS显著降低相关。
临床怎么用
- 对于接受尼达尼布治疗的IPF患者,动态监测CRPM斜率可能有助于识别5年死亡风险增高者。
- CRPM斜率对预后的提示作用在吡非尼酮治疗者中未观察到,提示抗纤维化药物选择时需考虑生物标志物动态。
局限性
- 研究纳入两个德国三级中心患者,外推性需进一步验证。
- 细胞实验使用人脐静脉内皮细胞而非IPF来源内皮细胞,机制结论需谨慎解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is characterized by an increase in proteolytic enzymes, including matrix metalloproteinases that degrade the extracellular matrix and markers of localized inflammation. Protein fragments (neoepitopes) are detectable in the circulation. RESEARCH QUESTION: Can short-term trajectories of neoepitopes after initiation of antifibrotic treatment predict therapy-related outcomes, including mortality, in patients with IPF? STUDY DESIGN AND METHODS: Two hundred three treatment-naive patients with IPF from 2 German tertiary centers were prospectively recruited. At baseline and within 6 months of nintedanib or pirfenidone treatment, serum concentrations of matrix metalloproteinase-degraded C-reactive protein neoepitope (CRPM), collagen III, and collagen 6 fragments, as well as procollagen 6, were measured. Association of neoepitopes and their longitudinal kinetics (positive/increasing or negative/declining slope) with mortality and progression- and transplant-free survival (PTFS) was analyzed. Modes of action of anti-fibrotic therapy on neoepitope kinetics were further investigated by cell culture experiments. RESULTS: Patient mean age was 71 years, and 20.7% were female. After baseline measurements, 50% received nintedanib, 35% received pirfenidone, and 15% received no antifibrotic treatment. Patients with a positive CRPM slope, treated with nintedanib, showed increased 5-year mortality (adjusted hazard ratio, 2.27; P = .020). In contrast, PTFS was significantly reduced with positive slopes of all tested neoepitopes. The association between positive CRPM slopes and impaired PTFS was confirmed by means of propensity score matching. In both cohorts, effects on PTFS were driven by the nintedanib-treated subcohort. Intercohort validation of the association between CRPM slopes and PTFS was evident. In cell-culture experiments, nintedanib exclusively modulated CRPM kinetics in human umbilical vein-derived endothelial cells, but not IPF-derived fibroblasts. This suggests that the observed nintedanib/CRPM related effect is partly mediated by endothelial cells. INTERPRETATION: Our results show that positive/increasing CRPM serum levels (slopes) were associated with worse 5-year survival in patients with IPF treated with nintedanib, but not pirfenidone. Nintedanib, but not pirfenidone, reduced endothelial CRPM formation in vitro. GERMAN CLINICAL TRIALS REGISTRATION: Nos.: DRKS00000017 and DRKS00000620; URL: https://drks.de/search/en/trial/.
引用
- Seeliger B, Ruwisch J, Bülow Sand JM, et al. Differential Effects of Antifibrotic Treatment on Outcome Prediction via Serial Matrix Metalloproteinase-Degraded C-Reactive Protein Neoepitope Levels in Idiopathic Pulmonary Fibrosis. Chest. 2025. PMID: 41033547. doi:10.1016/j.chest.2025.08.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。